key: cord-0893607-1dpc1b2t
authors: Criado, Paulo Ricardo; Giordani, Lucas Prezotto; Yoshimoto, Thais Akemi; Vieira, Ingrid Campos; Landman, Gilles; Pincelli, Thais Prota
title: Vasculitis in the setting of COVID‐19: From the disease to the vaccine. Report of a case of cutaneous vasculitis after immunization
date: 2022-02-20
journal: Dermatol Ther
DOI: 10.1111/dth.15367
sha: 29bfe050e731589306d258b54b5a4344b32fe539
doc_id: 893607
cord_uid: 1dpc1b2t

nan

Cutaneous vasculitis may be triggered by several factors, including infections or drugs, or may be related to underlying conditions, notably connective tissue disease or malignancies. Along the COVID-19 pandemic we have identified 11 case reports about COVID-19-associated cutaneous (Table S1) (Table S2) .

Based on these reports, we currently know that SARS-CoV-2 can cause different types of skin lesions, with leukocytoclastic vasculitis being one of them. However, cutaneous vasculitis following COVID-19 vaccination is a relatively rare event, with only 32 cases reported in the literature up to November 1, 2021: Thirteen cases occurred after the ChAdOx1 (AstraZeneca) vaccine (40.62%), 10 of them occurred after the first dose of the BNT16B2b2 (Pfizer) vaccine (31.25%), 8, 9 two cases after the Coronavac vaccine (6.25%), two cases after the COVAXIN 2 "inactivated virus" vaccine (6.25%), 10 We are adding a new case of cutaneous small-vessel vasculitis after COVID-19 immunization with the AstraZeneca vaccine.

A 61-year-old Caucasian woman presented with a 7-day history of intensely pruritic erythematous-purpuric macules involving the lower legs and feet that progressed within hours to involve the buttocks, axillae, and lateral aspects of the abdomen ( Figure 1A Most cases of cutaneous vasculitis related to COVID-19 vaccination occurred with vaccines involving the messenger RNA (mRNA) mechanism, 8, 9 with the exception of the COVAXIN. 10 The present patient represents a case of an immune reaction after immunization with a viral vector COVID-19 vaccine (AZD1222). Interestingly, this patient had no previous relevant medical history and negative autoimmune markers. The exact mechanism behind the development of cutaneous vasculitis after viral vector COVID-19 vaccine is still unclear. We hypothesize that immunogenicity generated by the Spike protein in the viral vector may play a role, with a similar immune mechanism to the SARS-CoV-2 infection-associated vasculitis. Further reports and studies are needed in order to better define a causal effect. Even with the possibility of severe adverse reactions after vaccine administration, we consider vaccines an essential tool to help control the current pandemic. Physicians must be aware of potential adverse reactions of COVID-19 vaccines so that they can be reported and adequately managed.

Approval from institutional review board has not been obtained as this submission is a case report and not a clinical trial/study involving participants.

COVID-19-associated leukocytoclastic vasculitis leading to gangrene and amputation

Leucocytoclastic vasculitis secondary to COVID-19 infection in a young child

Successful treatment of a bullous vasculitis with intravenous immunoglobulins in a COVID-19 patient

Exuberant bullous vasculitis associated with SARS-CoV-2 infection

Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection. Rheumatology (Oxford)

Leukocytoclastic vasculitis in a patient with COVID-19 with positive SARS-CoV-2 PCR in skin biopsy

Widespread cutaneous small vessel vasculitis secondary to COVID-19 infection

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registrybased study of 414 cases

Leukocytoclastic vasculitis flare following the COVID-19 vaccine

Asymmetric cutaneous vasculitis following COVID-19 vaccination with unusual eosinophil preponderance